BeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) shares passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.41 and traded as low as $0.73. BeyondSpring shares last traded at $0.7420, with a volume of 33,006 shares.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeyondSpring in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on BYSI
BeyondSpring Price Performance
BeyondSpring (NASDAQ:BYSI – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.49.
Institutional Trading of BeyondSpring
A hedge fund recently bought a new position in BeyondSpring stock. State Street Corp acquired a new stake in shares of BeyondSpring Inc. (NASDAQ:BYSI – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned approximately 0.57% of BeyondSpring as of its most recent filing with the Securities & Exchange Commission. 40.29% of the stock is currently owned by hedge funds and other institutional investors.
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.
Further Reading
- Five stocks we like better than BeyondSpring
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
